Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Non-Current Deffered Revenue (2019 - 2021)

Historic Non-Current Deffered Revenue for Fulcrum Therapeutics (FULC) over the last 3 years, with Q4 2021 value amounting to $1.7 million.

  • Fulcrum Therapeutics' Non-Current Deffered Revenue fell 4345.34% to $1.7 million in Q4 2021 from the same period last year, while for Dec 2021 it was $1.7 million, marking a year-over-year decrease of 4345.34%. This contributed to the annual value of $1.7 million for FY2021, which is 4345.34% down from last year.
  • Per Fulcrum Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $1.7 million for Q4 2021, which was down 4345.34% from $1.6 million recorded in Q3 2021.
  • Fulcrum Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $6.0 million during Q4 2019, with a 5-year trough of $1.5 million in Q3 2019.
  • In the last 3 years, Fulcrum Therapeutics' Non-Current Deffered Revenue had a median value of $2.1 million in 2019 and averaged $3.1 million.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first soared by 29063.52% in 2020, then crashed by 7247.28% in 2021.
  • Quarter analysis of 3 years shows Fulcrum Therapeutics' Non-Current Deffered Revenue stood at $6.0 million in 2019, then crashed by 50.57% to $3.0 million in 2020, then tumbled by 43.45% to $1.7 million in 2021.
  • Its Non-Current Deffered Revenue stands at $1.7 million for Q4 2021, versus $1.6 million for Q3 2021 and $1.7 million for Q2 2021.